Browse > Article
http://dx.doi.org/10.1186/s40824-016-0083-1

Liposomal delivery systems for intestinal lymphatic drug transport  

Ahn, Hyeji (Department of Bio and Brain Engineering, and Institute of Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST))
Park, Ji-Ho (Department of Bio and Brain Engineering, and Institute of Health Science and Technology, Korea Advanced Institute of Science and Technology (KAIST))
Publication Information
Biomaterials Research / v.20, no.4, 2016 , pp. 222-227 More about this Journal
Abstract
Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.
Keywords
Chylomicron; First-pass metabolism; Intestinal lymphatic transport; Lipid; Liposome;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Paliwal R, et al. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. J Pharm. 2009;29:181-8.
2 Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Disc. 2005;5:145-60.
3 Yoo J-W, et al. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Disc. 2011;10:521-35.   DOI
4 Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36-48.   DOI
5 Andar AU, et al. Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. Pharm Res. 2014;31:401-13.   DOI
6 Kim H, et al. Liposomal formulations for enhanced lymphatic drug delivery. Asian J Pharm Sci. 2013;8:96-103.   DOI
7 Iwanaga K, et al. Oral delivery of insulin by using surface coating liposomes: Improvement of stability of insulin in GI tract. Int J Pharm. 1997;157:73-80.   DOI
8 Kisel MA, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm. 2001;216:105-14.   DOI
9 Ling SSN, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug Dev Ind Pharm. 2006; 32:335-45.   DOI
10 Niu M, et al. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. Eur J Pharm Biopharm. 2012;81:265-72.   DOI
11 Niu M, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: A mechanistic study. Int J Pharm. 2014;460:119-30.   DOI
12 Huang Y-B, et al. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. J Drug Target. 2011;19:709-18.   DOI
13 Li X, et al. Novel mucus-penetrating liposomes as a potential oral drug delivery system: preparation, in vitro characterization, and enhanced cellular uptake. Int J Nanomedicine. 2011;6:3151-62.
14 Takeuchi H, et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release. 2003;86:235-42.   DOI
15 Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001;52:117-26.   DOI
16 Takeuchi H, et al. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res. 1996;13:896-901.   DOI
17 Kim HJ, Lee CM, Lee YB, et al. Preparation and mucoadhesive test of CSAloaded liposomes with different characteristics for the intestinal lymphatic delivery. Biotechnol Bioprocess Eng. 2005;10:516-21.   DOI
18 Trevaskis NL, et al. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Disc. 2015;14:781-803.   DOI
19 Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8: 2733-44.
20 Wasan KM, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Disc. 2008;7:84-99.   DOI
21 Shi Y, Burn P. Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Disc. 2004;3:695-710.   DOI
22 Porter CJH, et al. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50:61-80.   DOI
23 Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Disc. 2003;2:289-95.   DOI
24 Charman WNA, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986;34:175-8.   DOI
25 Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Disc. 2007;6: 231-48.   DOI
26 Redgrave TG. Chylomicron metabolism. Biochem Soc Trans. 2004;32:79-82.   DOI
27 Khoo S-M, et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci. 2001;90:1599-607.   DOI
28 Fricker G, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharma Res. 2010;27:1469-86.   DOI
29 Murakami M, et al. Enteral siRNA delivery technique for therapeutic gene silencing in the liver via the lymphatic route. Sci Rep. 2015;5:1-13.
30 Zhou C, et al. The preparation of a complex of insulin-phospholipids and their interaction mechanism. J Pept Sci. 2012;18:541-8.   DOI
31 Charman WN. Lipids, lipophilic drugs, and oral drug delivery-Some emerging concepts. J Pharm Sci. 2000;89:967-78.   DOI
32 Dahan A, et al. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release. 2008;126:1-9.   DOI
33 Khan MSY, Akhter M. Glyceride derivatives as potential prodrugs: synthesis, biological activit y and kinetic studies of glyceride derivatives of mefenamic acid. Pharmazie. 2005;60:110-4.
34 Caliph SM, et al. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats. J Pharm Sci. 2000;89:1073-84.   DOI
35 Attili-Qadri S, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci U S A. 2013;110:17498-503.   DOI
36 Fang G, et al. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv. 2015;5:437-96447.